Showing 1 - 10 of 12
Persistent link: https://www.econbiz.de/10013175838
Persistent link: https://www.econbiz.de/10011711300
Persistent link: https://www.econbiz.de/10013549058
Persistent link: https://www.econbiz.de/10014442033
Persistent link: https://www.econbiz.de/10015069685
Background: Decision-analytic modelling (DAM) has become a widespread method in health technology assessments (HTA), but the extent to which modelling is used differs among international HTA institutions. In Germany, the use of DAM is optional within HTAs of the German Institute of Medical...
Persistent link: https://www.econbiz.de/10010530072
Introduction: Until recently, adjuvant treatment options for higher stage resectable cutaneous melanoma were limited. Two studies with a similar set-up, published 2017, led to registration of targeted therapy for BRAF-mutated melanoma with dabrafenib and trametinib as well as of the...
Persistent link: https://www.econbiz.de/10012804643
Persistent link: https://www.econbiz.de/10012631361
Objectives: To estimate the cost savings and health benefits in the UK NHS that could be achieved if human milk usage in the NICU was increased. Methods: A systematic review established the disease areas with the strong sources of evidence of the short, medium and long-term benefits of human...
Persistent link: https://www.econbiz.de/10011587181
This paper aims to systematically review the cost-effectiveness evidence, and to provide a critical appraisal of the methods used in the model-based economic evaluation of CRC screening and subsequent surveillance. A search strategy was developed to capture relevant evidence published...
Persistent link: https://www.econbiz.de/10011593369